07:00 , Aug 12, 2013 |  BC Week In Review  |  Company News

Palau, Actavis deal

Actavis acquired worldwide rights to Palau's antifungal agent albaconazole, which is in development to treat vulvo-vaginal candidiasis, onychomycosis and other antifungal conditions. The broad spectrum oral antifungal has completed a Phase II trial to treat...